OBJECTIVE: To conduct bibliometrics analysis on studies of applied researches of pharmacogenomics in oncology, to investigate die current research situation in this field. METHODS: Web of Science was retrived, bibliometrics analysis was adopted to collect and analyze the collected studies from Jan. 1st 1982-Apr. 19th 2017 in terms of published year, nations and (or) regions, research institutes, journals, authors, research fields, cited frequencies, etc. RESULTS: 3 495 studies were involved finally, the number of studies presented an increasing trend during 1982-2013, which reached the top in 2013 and then gradually decreased. A total of 91 nations and (or) regions were involved, the number of studies in America was significantly more than that of other nations and (or) regions. 3 987 research institutions were involved, the University of Chicago ranked the first. These studies were published on 876 journals, 987 studies (28. 240% ) were published on the top 10 journals ranked in number of published studies, the first journals; 16 JCR categories were involved in the top 10 journals. 16 807 authors were involved, 140 of which had published over 10 studies; among the top 10 authors ranked in the number of published studies, 7 were from America, the author ranked the first was Mcleod IIL from the II. Lee Moffitt Cancer Center of America. These studies had involved 87 research fields, the top 4 were respectively medicine and pharmacology, oncology, gene genetics, biotechnology and applied microbiology. The 3 495 studies had been cited for 94 500 times, with an average cited frequency of 27.04 times, the correspondent authors of the top 3 studies ranked in cited frequency were respectively from Britain, Germany and France, the fourth to the tenth were from America; the top 1 study was “Systematic Identification of Genomic Markers of Drug Sensitivity in Cancer Cells”. CONCLUSIONS: The applied researches of pharmacogenomics had achieved great progresses in oncology, yet in a slowdown in recent years, researchers have paid most attention on the relationship between gene expression and the sensitivity of antineoplastic agents; at present, America owns the best research ability , our country also own well research ability, but there is still a certain gap between. [ABSTRACT FROM AUTHOR]